In an animal model of gastric cancer, a combination of EP16 and anti-PD-1 agent had a tumor growth inhibitory rate of 69%, whereas monotherapy with EP16 and anti-PD-1 had TGI of 32% and 51%, respectively [75]. Here, PDCD1 is linked to gastric cancer.